iconEarnings Announcement Before Market Open

Axsome Therapeutics Inc AXSM:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 1:05 PM EST
70.48quote price arrow up+3.12 (+4.63%)
Volume
214,886
52 week range
35.44 - 109.53

...

Loading . . .

KEY STATS

  • Open67.28
  • Day High71.74
  • Day Low66.54
  • Prev Close67.36
  • 52 Week High109.53
  • 52 Week High Date04/27/20
  • 52 Week Low35.44
  • 52 Week Low Date03/18/20
  • Market Cap2.632B
  • Shares Out37.34M
  • 10 Day Average Volume0.29M
  • Dividend-
  • Dividend Yield-
  • Beta2.56
  • 1 Year % Change-9.13

RATIOS/PROFITABILITY

  • EPS (TTM)-2.70
  • P/E (TTM)-26.12
  • Fwd P/E (NTM)-19.46
  • EBITDA (MRQ)-95.803M
  • ROE (MRQ)-138.71%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)35.51%

EVENTS

  • Earnings Date03/01/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Axsome Therapeutics Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain...
Herriot Tabuteau M.D.
Chairman
Mark Jacobson
Chief Operating Officer
Nick Pizzie CPA
Chief Financial Officer
Address
22 CORTLANDT STREET, 16TH FLOOR
New York, NY
10007
United States